+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Left Ventricular Dysfunction - Pipeline Review, H1 2020

  • ID: 4911668
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 49 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Armaron Bio Pty Ltd
  • Innopharmax Inc
  • Mesoblast Ltd
  • Quantum Genomics SA
  • Viscofan BioEngineering
  • MORE
Left Ventricular Dysfunction - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2020, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape.

Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heart beat and congested lungs. Risk factors include high blood pressure, diabetes, sleep apnea, alcoholism and coronary artery disease.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Left Ventricular Dysfunction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 1 respectively.

Left Ventricular Dysfunction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Left Ventricular Dysfunction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Left Ventricular Dysfunction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Left Ventricular Dysfunction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Left Ventricular Dysfunction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Armaron Bio Pty Ltd
  • Innopharmax Inc
  • Mesoblast Ltd
  • Quantum Genomics SA
  • Viscofan BioEngineering
  • MORE
  • Introduction
  • Report Coverage
  • Left Ventricular Dysfunction - Overview
  • Left Ventricular Dysfunction - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Left Ventricular Dysfunction - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Left Ventricular Dysfunction - Companies Involved in Therapeutics Development
  • Armaron Bio Pty Ltd
  • Innopharmax Inc
  • Mesoblast Ltd
  • Quantum Genomics SA
  • Shanghai Life Science & Technology
  • Takeda Pharmaceutical Co Ltd
  • Viscofan BioEngineering
  • Left Ventricular Dysfunction - Drug Profiles
  • AlloCSC-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • carvedilol CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • firibastat IR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MPC-150IM - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NP-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Left Ventricular Dysfunction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBC-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Left Ventricular Dysfunction - Dormant Projects
  • Left Ventricular Dysfunction - Discontinued Products
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Left Ventricular Dysfunction, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Left Ventricular Dysfunction - Pipeline by Armaron Bio Pty Ltd, H1 2020
  • Left Ventricular Dysfunction - Pipeline by Innopharmax Inc, H1 2020
  • Left Ventricular Dysfunction - Pipeline by Mesoblast Ltd, H1 2020
  • Left Ventricular Dysfunction - Pipeline by Quantum Genomics SA, H1 2020
  • Left Ventricular Dysfunction - Pipeline by Shanghai Life Science & Technology, H1 2020
  • Left Ventricular Dysfunction - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Left Ventricular Dysfunction - Pipeline by Viscofan BioEngineering, H1 2020
  • Left Ventricular Dysfunction - Dormant Projects, H1 2020
  • Left Ventricular Dysfunction - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Left Ventricular Dysfunction, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Armaron Bio Pty Ltd
  • Innopharmax Inc
  • Mesoblast Ltd
  • Quantum Genomics SA
  • Shanghai Life Science & Technology
  • Takeda Pharmaceutical Co Ltd
  • Viscofan BioEngineering
Note: Product cover images may vary from those shown
Adroll
adroll